Ionis Pharmaceuticals

Ionis and Roche to develop RNAi AMD drug in $760m deal

https://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/

FDA approves Ionis/Akcea’s Tegsedi RNAi drug, taking on Alnylam

https://pharmaphorum.com/news/fda-approves-ionis-akceas-tegsedi-competing-against-alnylam/

US regulators reject Akcea and Ionis rare disease drug

https://pharmaphorum.com/news/us-regulators-reject-akcea-ionis-rare-disease-drug/

AZ grabs licence as Ionis NASH drug heads to the clinic

https://pharmaphorum.com/news/az-grabs-licence-ionis-nash-drug-heads-clinic/

AZ signs kidney drug deal with Ionis for up to $330m

https://pharmaphorum.com/news/az-buys-kidney-disease-drug-from-ionis-for-up-to-330m/

Roche takes on development of potential Huntington’s breakthrough

https://pharmaphorum.com/news/roche-takes-development-potential-huntingtons-breakthrough/

Alnylam soars after drug success, paving way for RNAi era

https://pharmaphorum.com/news/alnylam-shares-jump-rnai-drug-succeeds-rare-disease-trial/

Ionis to file rare disease drug after GSK declines option

https://pharmaphorum.com/news/ionis-gsk-declines/

Novartis, BMS, Janssen unveil R&D deals

https://pharmaphorum.com/news/novartis-bms-janssen-jp-morgan/

Close in 10 seconds

Pharmaphorum.com

Search